BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 38720797)

  • 1. Efficiency of moderately hypofractionated radiotherapy in NSCLC cell model.
    Lüdeking M; Stemwedel K; Ramachandran D; Grosche S; Christiansen H; Merten R; Henkenberens C; Bogdanova NV
    Front Oncol; 2024; 14():1293745. PubMed ID: 38720797
    [TBL] [Abstract][Full Text] [Related]  

  • 2. In Vitro Radiobiological Advantages of Hypofractionation Compared with Conventional Fractionation: Early-Passage NSCLC Cells are Less Aggressive after Hypofractionation.
    Zhang H; Wan C; Huang J; Yang C; Qin Y; Lu Y; Ma J; Wu B; Xu S; Wu G; Yang K
    Radiat Res; 2018 Dec; 190(6):584-595. PubMed ID: 30234458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The minimal FLASH sparing effect needed to compensate the increase of radiobiological damage due to hypofractionation for late-reacting tissues.
    Böhlen TT; Germond JF; Bourhis J; Bailat C; Bochud F; Moeckli R
    Med Phys; 2022 Dec; 49(12):7672-7682. PubMed ID: 35933554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer: 5-year outcomes of the HYPO-RT-PC randomised, non-inferiority, phase 3 trial.
    Widmark A; Gunnlaugsson A; Beckman L; Thellenberg-Karlsson C; Hoyer M; Lagerlund M; Kindblom J; Ginman C; Johansson B; Björnlinger K; Seke M; Agrup M; Fransson P; Tavelin B; Norman D; Zackrisson B; Anderson H; Kjellén E; Franzén L; Nilsson P
    Lancet; 2019 Aug; 394(10196):385-395. PubMed ID: 31227373
    [TBL] [Abstract][Full Text] [Related]  

  • 5. One versus three weeks hypofractionated whole breast radiotherapy for early breast cancer treatment: the FAST-Forward phase III RCT.
    Brunt AM; Haviland JS; Wheatley DA; Sydenham MA; Bloomfield DJ; Chan C; Cleator S; Coles CE; Donovan E; Fleming H; Glynn D; Goodman A; Griffin S; Hopwood P; Kirby AM; Kirwan CC; Nabi Z; Patel J; Sawyer E; Somaiah N; Syndikus I; Venables K; Yarnold JR; Bliss JM;
    Health Technol Assess; 2023 Nov; 27(25):1-176. PubMed ID: 37991196
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Modern hypofractionation schedules for tangential whole breast irradiation decrease the fraction size-corrected dose to the heart.
    Appelt AL; Vogelius IR; Bentzen SM
    Clin Oncol (R Coll Radiol); 2013 Mar; 25(3):147-52. PubMed ID: 22910644
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of Hypofractionated Radiotherapy on Patient-reported Outcomes in Prostate Cancer: Results up to 5 yr in the CHHiP trial (CRUK/06/016).
    Staffurth JN; Haviland JS; Wilkins A; Syndikus I; Khoo V; Bloomfield D; Parker C; Logue J; Scrase C; Birtle A; Malik Z; Panades M; Eswar C; Graham J; Russell M; Ferguson C; O'Sullivan JM; Cruickshank CA; Dearnaley D; Hall E;
    Eur Urol Oncol; 2021 Dec; 4(6):980-992. PubMed ID: 34489210
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Variability of α/β ratios for prostate cancer with the fractionation schedule: caution against using the linear-quadratic model for hypofractionated radiotherapy.
    Cui M; Gao XS; Li X; Ma M; Qi X; Shibamoto Y
    Radiat Oncol; 2022 Mar; 17(1):54. PubMed ID: 35303922
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Hypofractionation for clinically localized prostate cancer.
    Hickey BE; James ML; Daly T; Soh FY; Jeffery M
    Cochrane Database Syst Rev; 2019 Sep; 9(9):CD011462. PubMed ID: 31476800
    [TBL] [Abstract][Full Text] [Related]  

  • 10. High-dose accelerated hypofractionated three-dimensional conformal radiotherapy (at 3 Gy/fraction) with concurrent vinorelbine and carboplatin chemotherapy in locally advanced non-small-cell lung cancer: a feasibility study.
    Liu YE; Lin Q; Meng FJ; Chen XJ; Ren XC; Cao B; Wang N; Zong J; Peng Y; Ku YJ; Chen Y
    Radiat Oncol; 2013 Aug; 8(1):198. PubMed ID: 23937855
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Hypofractionated radiotherapy versus conventionally fractionated radiotherapy for patients with intermediate-risk localised prostate cancer: 2-year patient-reported outcomes of the randomised, non-inferiority, phase 3 CHHiP trial.
    Wilkins A; Mossop H; Syndikus I; Khoo V; Bloomfield D; Parker C; Logue J; Scrase C; Patterson H; Birtle A; Staffurth J; Malik Z; Panades M; Eswar C; Graham J; Russell M; Kirkbride P; O'Sullivan JM; Gao A; Cruickshank C; Griffin C; Dearnaley D; Hall E
    Lancet Oncol; 2015 Dec; 16(16):1605-16. PubMed ID: 26522334
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Accelerated hypofractionated three-dimensional conformal radiation therapy (3 Gy/fraction) combined with concurrent chemotherapy for patients with unresectable stage III non-small cell lung cancer: preliminary results of an early terminated phase II trial.
    Ren XC; Wang QY; Zhang R; Chen XJ; Wang N; Liu YE; Zong J; Guo ZJ; Wang DY; Lin Q
    BMC Cancer; 2016 Apr; 16():288. PubMed ID: 27108080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving Outcomes in NSCLC: Optimum Dose Fractionation in Radical Radiotherapy Matters.
    Brada M; Forbes H; Ashley S; Fenwick J
    J Thorac Oncol; 2022 Apr; 17(4):532-543. PubMed ID: 35092841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Locally advanced inoperable primary or recurrent non-small cell lung cancer treated with 4-week hypofractionated radiation therapy (3 Gy/fraction).
    Valeriani M; Marinelli L; Nicosia L; Reverberi C; De Sanctis V; Mollo D; Osti MF
    Radiol Med; 2019 Dec; 124(12):1324-1332. PubMed ID: 31317381
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effectiveness of accelerated radiotherapy for patients with inoperable non-small cell lung cancer (NSCLC) and borderline prognostic factors without distant metastasis: a retrospective review.
    Nguyen LN; Komaki R; Allen P; Schea RA; Milas L
    Int J Radiat Oncol Biol Phys; 1999 Jul; 44(5):1053-6. PubMed ID: 10421538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conventional Versus Different Hypofractionated Radiotherapy Dosage Schedules in Postmastectomy Advanced Breast Cancer.
    Jain N; Sharma R; Sachdeva K; Kaur A; Sudan M
    J Med Phys; 2022; 47(2):141-144. PubMed ID: 36212213
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Intensity-modulated fractionated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): acute toxicity findings from an international, randomised, open-label, phase 3, non-inferiority trial.
    Brand DH; Tree AC; Ostler P; van der Voet H; Loblaw A; Chu W; Ford D; Tolan S; Jain S; Martin A; Staffurth J; Camilleri P; Kancherla K; Frew J; Chan A; Dayes IS; Henderson D; Brown S; Cruickshank C; Burnett S; Duffton A; Griffin C; Hinder V; Morrison K; Naismith O; Hall E; van As N;
    Lancet Oncol; 2019 Nov; 20(11):1531-1543. PubMed ID: 31540791
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hypofractionated radiotherapy in locally advanced bladder cancer: an individual patient data meta-analysis of the BC2001 and BCON trials.
    Choudhury A; Porta N; Hall E; Song YP; Owen R; MacKay R; West CML; Lewis R; Hussain SA; James ND; Huddart R; Hoskin P;
    Lancet Oncol; 2021 Feb; 22(2):246-255. PubMed ID: 33539743
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Systematic review of hypofractionated radiation therapy for prostate cancer.
    Zaorsky NG; Ohri N; Showalter TN; Dicker AP; Den RB
    Cancer Treat Rev; 2013 Nov; 39(7):728-36. PubMed ID: 23453861
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hypofractionated Radiotherapy for Localized Prostate Cancer: A Challenging Accelerated Hypofractionated Radiotherapy.
    Yamazaki H; Nakamura S; Suzuki G; Yoshida K; Yoshioka Y; Koizumi M; Ogawa K
    Anticancer Res; 2015 Oct; 35(10):5167-77. PubMed ID: 26408674
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.